Stifel Starts Protagonist Therapeutics (PTGX) at Buy

January 29, 2018 4:26 AM
Stifel initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Buy rating and a price target of $32.00.Analyst Adam Walsh ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot New Coverage New Coverage